SCHEMBL5648366

SCHEMBL5648366

CCN(CC)CCCNC(=O)c1ccc(-c2nc3ccc(C(F)(F)F)cc3[nH]2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 5/20 0.47
FLT3 P36888 1/20 0.46
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
NSD2 O96028 1/20 0.45
RAD52 P43351 1/20 0.44
F9 P00740 1/20 0.44
TP53 P04637 2/20 0.42
ITGB3 P05106 3/20 0.41
ITGA2B P08514 3/20 0.41
NPBWR1 P48145 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648371 0.93 ACKR3 (0.47) ACKR3FLT3KMT2AALDH1A1LMNA
SCHEMBL5653261 0.84 FLT3 (0.55) FLT3F9NPBWR1HDAC4HDAC2
SCHEMBL5650339 0.81 ALDH1A1 (0.49) ACKR3KMT2AALDH1A1LMNAMEN1
SCHEMBL5650343 0.81 ALDH1A1 (0.49) ACKR3KMT2AALDH1A1LMNAMEN1
SCHEMBL5651747 0.80 FLT3 (0.53) FLT3KMT2ALMNAF9TP53
SCHEMBL5651069 0.80 MEN1 (0.51) FLT3KMT2AALDH1A1LMNAMEN1
SCHEMBL5650980 0.79 FLT3 (0.53) FLT3KMT2AF9TP53ITGB3
SCHEMBL5653988 0.78 FLT3 (0.51) FLT3F9HDAC4HDAC2HDAC8
SCHEMBL5653244 0.77 FLT3 (0.51) FLT3KMT2AF9HDAC4HDAC2
SCHEMBL5648361 0.77 FLT3 (0.43) FLT3KMT2AF9ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 ACKR3 635/4885FLT3 1968/4885KMT2A 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.